BetterLife Pharma (BETRF) Total Non-Current Liabilities (2011 - 2026)
BetterLife Pharma (BETRF) posted quarterly Total Non-Current Liabilities of $4.8 million for Q2 2026, up 12.54% year-over-year from $4.2 million in Q2 2025, and up 24271.24% quarter-over-quarter from $19580.8 in Q1 2026.
BetterLife Pharma (BETRF) Total Non-Current Liabilities (2011 - 2026) Analysis & Trends
BetterLife Pharma's Total Non-Current Liabilities history runs 12 years deep, the most recent figure standing at $4.8 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities rose 12.54% year-over-year to $4.8 million; the TTM figure through Apr 2026 stood at $4.8 million (up 12.54% YoY), while the FY2026 annual figure was $19580.8, down 43.4% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $4.8 million, up from $19580.8 in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $6.1 million in Q2 2024, with the low at -$67453.0 in Q1 2024.
- The 5-year median for Total Non-Current Liabilities is $4.8 million (2026), against an average of $3.3 million.
- The sharpest annual moves came in 2023 and 2024: Total Non-Current Liabilities soared 478.05% in 2023, then tumbled 339.52% in 2024.
- BetterLife Pharma's Total Non-Current Liabilities stood at $5.2 million in 2022, then dropped by 1.24% to $5.1 million in 2023, then declined by 4.31% to $4.9 million in 2024, then retreated by 13.35% to $4.2 million in 2025, then advanced by 12.58% to $4.8 million in 2026.
- Business Quant data shows BETRF's Total Non-Current Liabilities at $4.8 million in Q2 2026, $19580.8 in Q1 2026, and $4.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | BetterLife Pharma | 36.45 Mn | 36.42 Mn | - | 4.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 4.77 Mn |
| Jan 31, 2026 | 19,580.76 |
| Jul 31, 2025 | 4.24 Mn |
| Apr 30, 2025 | 4.24 Mn |
| Jan 31, 2025 | 34,597.92 |
| Oct 31, 2024 | 4.89 Mn |
| Jul 31, 2024 | 5.57 Mn |
| Apr 30, 2024 | 6.05 Mn |
| Jan 31, 2024 | -67,452.98 |
| Oct 31, 2023 | 5.11 Mn |
| Jul 31, 2023 | 5.24 Mn |
| Apr 30, 2023 | 5.05 Mn |
| Jan 31, 2023 | -15,346.86 |
| Oct 31, 2022 | 5.18 Mn |
| Jul 31, 2022 | 5.45 Mn |
| Apr 30, 2022 | 874,129.12 |
| Jan 31, 2022 | -13,652.61 |
| Oct 31, 2021 | 3.01 Mn |
| Jul 31, 2021 | 3.59 Mn |
| Apr 30, 2021 | 4.15 Mn |